According to the companies, current strategies for developing new anticancer drugs rely heavily on preclinical testing in cancer cell lines and their derived in-vivo xenograft models. A significant limitation to current preclinical testing is the use of highly passaged cancer cell lines grown on plastic. Improved preclinical models are required to advance understanding of the molecular aberrations that underpin cancer.

 

Cell-able Oncology will allow primary tumor cells to grow in 3D cultures that more closely resemble in-vivo-like conditions. Models grown in 3D culture conditions coupled with molecular characterization provide a stronger correlation to clinical outcomes than conventional preclinical anticancer drug testing, the companies say.

 

“Molecular Response’s pharmaceutical research services, combined with Cell-able Oncology, will provide researchers the right tools to perform transformative drug discovery with patient-derived primary tumor cells and focused molecular targets that enable drug sensitivity testing that is strongly correlated to clinical outcomes,” said Transparent CEO Rocky Kato in a statement.